Litcius/Paper detail

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial

Rachel G. Casseres, Lisa Prussick, Pedro Zancanaro, Brooke Rothstein, Deep Joshipura, Ami Saraiya, Yana Turkowski, Shiu Chung Au, Abdulaziz Alomran, Rana Abdat, Minawaer Abudu, Courtney Kachuk, Nicole Dumont, Alice B. Gottlieb, David Rosmarin

2020Journal of the American Academy of Dermatology84 citationsDOIOpen Access PDF

Topics & Concepts

Hidradenitis suppurativaMedicineSecukinumabProinflammatory cytokineInterleukin 17DermatologyPsoriasisTumor necrosis factor alphaAdalimumabPopulationInterleukinImmunologyCytokineInternal medicineDiseaseInflammationEnvironmental healthPsoriatic arthritisHidradenitis Suppurativa and TreatmentsColorectal and Anal Carcinomas
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial | Litcius